UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 24, 2007
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 995-2500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On October 24, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce that huC242-DM4 Phase I findings, preclinical support for its Phase II evaluation in gastric cancer, and additional information on the activation of TAP compounds inside tumors are being reported at the AACR-NCI-EORTC “Molecular Targets and Cancer Therapeutics” International Conference being held in San Francisco, CA.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) The following exhibit is being filed herewith:
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated October 24, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ImmunoGen, Inc. |
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: October 25, 2007 |
|
/s/ Daniel M. Junius |
|
|
|
|
|
|
|
|
|
Daniel M. Junius |
|
|
|
|
Executive Vice President and Chief Financial Officer |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated October 24, 2007 |
4